Summit Therapeutics Share Discussion Threads

[hugus maximus] 05/9/2017 19:51

and Michael Miles the man with the questions ... flip you must be REALLY old euroto!

[euroto] 05/9/2017 18:13

Bob Danvers Walker with the gong.

[hugus maximus] 05/9/2017 17:48

Indeed surely today's piece of info is in anticipation of the contents?!

Who else is old enough to remember the "Yes - No - Interlude"?

"Open the box ... no take the money!"

[luminoso] 05/9/2017 16:40

I think Box 1 may be the best we can hope for at this stage, with the lacklustre interest of majors in anti-biotics at the moment. I think I'll take the bankers' offer, thanks Noel, as i don't really want to open Box 2 or 3 !

[waterloo01] 05/9/2017 16:27

Surely it's the last piece in place before Glyn finally opens the box and tells us what's inside! The audio cast he seemed to be suggesting it was close.

Just for fun...

Box 1 - 100% funding of phase 3's, no upfront, 50/50 JV (actually 40/40/20 - Wellcome share)

Box 2 - ?

Box 3 - ?

[luminoso] 05/9/2017 16:19

nasdaq's not much warmer yet !

[football] 05/9/2017 14:27

The water is cold in Marazion today

[algernon2] 05/9/2017 13:00

Come on back in Al the water is warm!

[hugus maximus] 05/9/2017 12:38

I stand pun corrected ... of course there is Van the Man El Cheapo, but perhaps FID has already shown overall cost savings in terms of hospital costs? So at £1500 one argues that RID is the current best in class. It will be interesting to see what the NASDAQ makes of this. It could be a good day there as this is their first day back after Labor Day weekend and the children will all be lined up in their new school uniforms ready for a new term.

[waterloo01] 05/9/2017 12:33

Resistance (pun intended) is vanco which is priced at about £100. Key is costs saved by better outcome (ie lower recurrence) and therefore hospital costs

[hugus maximus] 05/9/2017 12:30

Thanks Waterloo ... so if £900 v £1500 is the comparison, that makes RID the best bet on the market.

[chrisatrdg] 05/9/2017 12:28

SP is starting to fly & many Buys hopefully a re-rating & a prelude to a C-Diff deal soon before the end of summer.I am looking forward to NASDAQ opening this afternoon.

[waterloo01] 05/9/2017 12:22

I think is priced about £1500 per treatment. Can't recall prospective price for RDZ

Edit: HC Wainwright note has a model with a £900 price point for RDZ

[hugus maximus] 05/9/2017 12:15

A strong positive market reaction.

If RID can be sold much cheaper than FID they have a winner. The overall "cure" results are around the same (the detail that's really strong long term is the addition of RID patients gut wall being left in better condition) However, I believe the strength here will be that RID can compete one to one with FID but should be cheaper on the market.

Does anyone have an idea of what that price comparison is?

[algernon2] 05/9/2017 12:05

Rns: More good news.

"Summit Therapeutics plc Summit Therapeutics Plc : Positive Top-line Phase 2 Results"

[hugus maximus] 01/9/2017 23:01

Enthusiasm on the NASDAQ again this evening ... which cheers things along a little.

[abergele] 31/8/2017 18:53

Going well so far in the USA, ,is this a guide to tomorrows start..better get in early if you want to top up,so far bodes well...fingers X'd....gla lth's

[chrisatrdg] 31/8/2017 13:48

Not a bad conference call - the elephant in the room is when will we get that RNS on a C-Diff deal.Good to hear the various questions which shows interest from various sectors.Good to see a marginal increase in the AIM share price so far today & will be interesting to see what the reaction will be on the NASDAQ this afternoon.

[football] 31/8/2017 13:07

Summit Therapeutics DMD trial underway; mulls funding options for c.diff trial

12:25 31 Aug 2017

The company is developing two drugs - one for a rare muscle wasting disease, the other a next-generation antibiotic
Summit Therapeutics PLC’s (LON:SUMM, NASDAQ:SMMT) interim results statement charted a period of significant progress for its two main drug candidates.

It is developing Ezutromid for Duchenne muscular dystrophy (DMD), a rare muscle wasting disease that affects boys, and Ridinilazole, a next-generation antibiotic.

The former has completed enrolment for its PhaseOut phase II clinical trial, which triggered a £17.2mln milestone payment from partner Sarepta, the US group.

Study underway
The study recruited 40 patients in the US and UK and will take 48 weeks to complete.

Researchers will assess how Ezutromid affects muscle structure, health and function.

Data from the half-way stage is expected in the first quarter of next year with the trial set to close in the third quarter.

Funding options
In the update, Summit said it was “exploring various funding options” for Ridinilazole, which is thought to be effective against multiple different strains of the difficult-to-treat infection c.difficile (CDI).

It may seek a partnership or “non-dilutive funding” such as a government grant or philanthropic contribution ahead of phase III trials in the first half of next year.

It is also believed to be superior to existing medications such as vancomycin and metronidazole.

“We believe ridinilazole can become a new, urgently needed frontline therapy for this serious infectious disease,” said chief executive Glyn Edwards.

Sarepta boost
The company’s figures showed it was sitting on £28.1mln at the end July following receipt of the Sarepta payment.

As well as boosting the bank balance, the income meant Summit was able to post a profit of £6.2mln for the six months to July 31, which compared with an £11.9mln loss for the same period last year.

Research and development expenses were £11.6mln.

Edwards was upbeat on the prospects for Summit.

"We look forward to an exciting and important period ahead as we continue advancing these two assets that have the potential to improve the quality of life of patients and families living with DMD and CDI," he said.